This clinical trial is focused on patients with aortic valve stenosis, a condition where the valve between the heart and the main artery becomes narrowed, affecting blood flow. The study aims to compare two different approaches to prevent blood clots and bleeding after a procedure called transcatheter aortic valve implantation (TAVI). One approach uses a personalized treatment plan guided by computed tomography (CT) scans, while the other uses a standard lifelong single antiplatelet therapy. Antiplatelet therapy involves medications that help prevent blood cells called platelets from clumping together to form clots.

The medications being studied include Acenocoumarol, Fenprocoumon, Prasugrel, Apixaban, Clopidogrel, Warfarin, Ticagrelor, and Acetylsalicylic Acid (commonly known as aspirin). Some participants will receive these medications, while others may receive a placebo. The purpose of the study is to determine if the personalized treatment plan is more effective in reducing the risk of heart-related deaths, blood clots, and bleeding events compared to the standard treatment.

Participants in the study will be randomly assigned to one of the two treatment groups. They will be monitored over time to assess the occurrence of any heart-related events, blood clots, or bleeding. The study will also evaluate the overall health and quality of life of participants, as well as their adherence to the medication regimen. The trial is expected to continue until 2027, with regular follow-ups to gather comprehensive data on the effectiveness and safety of the treatments being tested.